Clinical trial
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled…
NCT00021697 · Avanir Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00021697 |
|---|---|
| Title | Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS |
| Official title | A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis |
| Lead sponsor | Avanir Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Amyotrophic Lateral Sclerosis |
| Intervention type | Drug |
| Interventions | AVP-923 |
| Enrollment | 100 |
| Start date | Jan 1, 2001 |
| Primary completion | Apr 1, 2002 |
| Completion | Apr 1, 2002 |
| First posted | Aug 3, 2001 |
| Last update posted | Jul 14, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: